HKD 0.03
(4.17%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 503.46 Million HKD | 15.05% |
2022 | 546.6 Million HKD | 8.67% |
2021 | 502.98 Million HKD | 8.67% |
2020 | 462.85 Million HKD | -3.92% |
2019 | 481.71 Million HKD | 26.88% |
2018 | 379.68 Million HKD | 35.14% |
2017 | 280.96 Million HKD | 132.56% |
2016 | 120.81 Million HKD | 115.71% |
2015 | 56 Million HKD | 76.51% |
2014 | 31.73 Million HKD | -16.57% |
2013 | 38.03 Million HKD | 302.97% |
2012 | 9.43 Million HKD | 630.22% |
2011 | -1.78 Million HKD | 99.67% |
2010 | -537.71 Million HKD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 264.31 Million HKD | 0.0% |
2023 Q1 | 99.2 Million HKD | -66.99% |
2023 Q2 | 318.03 Million HKD | 220.59% |
2023 FY | 628.84 Million HKD | 15.05% |
2023 Q4 | 310.81 Million HKD | 103.77% |
2023 Q3 | 152.52 Million HKD | -52.04% |
2022 Q1 | 163.64 Million HKD | -39.8% |
2022 FY | 546.6 Million HKD | 8.67% |
2022 Q4 | 300.55 Million HKD | 115.78% |
2022 Q3 | 139.28 Million HKD | -58.34% |
2022 Q2 | 334.31 Million HKD | 104.3% |
2021 FY | 502.98 Million HKD | 8.67% |
2021 Q1 | 133.94 Million HKD | -51.13% |
2021 Q2 | 283.76 Million HKD | 111.85% |
2021 Q3 | 88.48 Million HKD | -68.82% |
2021 Q4 | 271.81 Million HKD | 207.19% |
2020 FY | 462.85 Million HKD | -3.92% |
2020 Q1 | 104.9 Million HKD | -53.7% |
2020 Q2 | 267.32 Million HKD | 154.83% |
2020 Q4 | 274.09 Million HKD | 0.0% |
2019 Q2 | 214.21 Million HKD | 77.52% |
2019 Q3 | 135.73 Million HKD | -36.63% |
2019 Q1 | 120.67 Million HKD | 25.04% |
2019 FY | 481.71 Million HKD | 26.88% |
2019 Q4 | 226.56 Million HKD | 66.91% |
2018 Q2 | 117.6 Million HKD | 0.0% |
2018 Q4 | 96.5 Million HKD | 0.0% |
2018 FY | 379.68 Million HKD | 35.14% |
2018 Q1 | 117.6 Million HKD | 33.05% |
2018 Q3 | 96.5 Million HKD | -17.94% |
2017 Q1 | 60.64 Million HKD | 12.2% |
2017 FY | 280.96 Million HKD | 132.56% |
2017 Q4 | 88.39 Million HKD | 0.0% |
2017 Q3 | 88.39 Million HKD | 45.76% |
2017 Q2 | 60.64 Million HKD | 0.0% |
2016 Q2 | 10.38 Million HKD | 0.0% |
2016 Q4 | 54.05 Million HKD | 0.0% |
2016 Q3 | 54.05 Million HKD | 420.52% |
2016 Q1 | 10.38 Million HKD | -54.54% |
2016 FY | 120.81 Million HKD | 115.71% |
2015 Q2 | 7.77 Million HKD | 0.0% |
2015 Q3 | 22.84 Million HKD | 193.71% |
2015 Q4 | 22.84 Million HKD | 0.0% |
2015 FY | 56 Million HKD | 76.51% |
2015 Q1 | 7.77 Million HKD | 61.04% |
2014 Q3 | 4.83 Million HKD | -52.54% |
2014 Q4 | 4.83 Million HKD | 0.0% |
2014 Q2 | 10.17 Million HKD | 0.0% |
2014 Q1 | 10.17 Million HKD | 107.04% |
2014 FY | 31.73 Million HKD | -16.57% |
2013 Q3 | 4.91 Million HKD | -18.58% |
2013 FY | 38.03 Million HKD | 302.97% |
2013 Q1 | 6.03 Million HKD | -52.21% |
2013 Q2 | 6.03 Million HKD | 0.0% |
2013 Q4 | 4.91 Million HKD | 0.0% |
2012 FY | 9.43 Million HKD | 630.22% |
2012 Q3 | 12.63 Million HKD | 435.41% |
2012 Q2 | 2.35 Million HKD | 0.0% |
2012 Q4 | 12.63 Million HKD | 0.0% |
2012 Q1 | 2.35 Million HKD | 0.0% |
2011 Q2 | -10.38 Million HKD | 0.0% |
2011 Q4 | 2.35 Million HKD | 122.72% |
2011 FY | -1.78 Million HKD | 99.67% |
2011 Q1 | -10.38 Million HKD | 0.0% |
2011 Q3 | -10.38 Million HKD | 0.0% |
2010 Q4 | -10.38 Million HKD | 92.58% |
2010 Q1 | -139.99 Million HKD | 0.0% |
2010 Q2 | -139.99 Million HKD | 0.0% |
2010 FY | -537.71 Million HKD | 0.0% |
2010 Q3 | -139.99 Million HKD | 0.0% |
2009 Q4 | -139.99 Million HKD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Pak Fah Yeow International Limited | 24.42 Million HKD | -1961.345% |
Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 86.959% |
Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -1317.128% |
Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -42.248% |
Qianhai Health Holdings Limited | 17.1 Million HKD | -2843.884% |
Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 14.811% |
Essex Bio-Technology Limited | 1.22 Billion HKD | 59.034% |
PuraPharm Corporation Limited | 216.62 Million HKD | -132.408% |
SSY Group Limited | 1.98 Billion HKD | 74.582% |
JBM (Healthcare) Limited | 163.87 Million HKD | -207.222% |
Jacobson Pharma Corporation Limited | 287.34 Million HKD | -75.21% |
China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 98.285% |